Cheshire bio business goes Dutch in sale to buy-and-build
A Dutch bioanalyis business Synexa Life Sciences has bought Alderley Analytical, an independent bioanalytical Contract Research Organisation (CRO) based in Tytherington Business Park near Macclesfield.
The acquisition is part of Synexa’s ‘buy and build’ growth strategy, driven by the company’s vision to become ‘the scientific partner of choice for biomarker and bioanalytical solutions’.
Synexa is backed by major European healthcare investor Gilde Healthcare.
The acquisition will expand Synexa’s capacity and broaden its range of analytical platforms across LC-MS/MS, enabling Synexa to strengthen its comprehensive suite of bioanalytical services and deepen its scientific offering to customers.
“Acquiring Alderley Analytical is a pivotal step in Synexa’s growth strategy, enhancing our capabilities in bioanalytical services and broadening our global reach. This integration will enable us to offer a more comprehensive range of services, such as Mass Spectrometry, and drive further innovation in biomarker and bioanalytical solutions. We are thrilled to welcome the Alderley team to Synexa and look forward to integrating our strengths,” said Emile Lens, the CEO of Synexa Life Sciences.
Alderley Analytical, founded in 2013 and operational since 2014, has grown significantly since the initial investment. The company now employs around 60 staff and over 200 clients and has recently relocated to specially designed laboratories at Tytherington Business Park.
The deal represents an exit for North West fund manager River Capital. The initial six-figure investment was made in July 2015 through the North West Biomedical Fund, which was initially managed by SPARK Impact and who have since operationally merged with River Capital.
This investment has yielded “substantial” returns, highlighting the success of both Alderley Analytical and River Capital’s investment strategy.
Jerry Mobbs, Portfolio Director River Capital said: “Our investment in Alderley Analytical exemplifies River Capital’s commitment to supporting innovative businesses in the North West.
“The company’s growth from a startup to a major player in the bioanalytical services sector is a testament to the hard work of its founders and the potential of the region’s biomedical industry.”
Paul Holme, Co-Founder and Director Alderley Analytical said: “As we enter this new phase with Synexa Life Sciences, we’re grateful for the early support from River Capital. Their investment allowed us to build a company that delivers high-quality, bespoke bioanalytical services to pharmaceutical, biotech, and CRO clients worldwide.”
He added: “This acquisition represents a significant opportunity to enhance our teams’ bioanalytical services and broaden our impact on drug development. We are excited by the new possibilities of providing greater value to our customers and supporting the further advancement of innovative therapies.”
Corporate Finance advisors to the Alderley Analytical were Cowgills, led by James Kennedy, and lawyers acting were Slater Heelis. Lawyers for River Capital were Brabners Liverpool office.